BioSpace News Archive

Axogen, Inc. today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will present at the Piper Sandler 35th Annual Healthcare Conference in New York, NY, on Thursday, November 30, 2023, at 8:50 a.m. E.T.

ASLAN Pharmaceuticals today announced Dr Carl Firth, CEO, will participate in a fireside discussion at the Piper Sandler Healthcare Conference.

Plus Therapeutics, Inc. today announced positive data from the ongoing ReSPECT-GBM Phase 2 trial evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM) at the Society for NeuroOncology (SNO) 28th Annual Meeting held November 15-19, 2023 in Vancouver, Canada.

On November 20, 2023 , Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US$210 million and bringing in the strategic investors, Temasek, Highlight Capital (HLC), and True Light.

Labcorp announced today the completion of the previously announced transaction with Legacy Health to acquire select assets of Legacy’s outreach laboratory business.

On November 20 , 2023, Porton Advanced announced a strategic partnership with Ascle Therapeutics to jointly develop and produce NK cells, assist in the development and innovation in gene and cell therapy, and accelerate the application of NK cells in cancer prevention, beauty, and anti-aging.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2023, and provided corporate and portfolio updates.

Harrow today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences.

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.

Novartis will present data from over 100 trials across its breast cancer and hematology portfolios at the 2023 San Antonio Breast Cancer Symposium and the American Society of Hematology Annual Meeting & Exposition.